Tolterodine A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data

Life Sciences

Volumn 60, Issue 13-14, 1997, Pages 1129-1136

  Nilvebrant, L ^a   Hallen B ^a,b   Larsson, G ^a  

^a Medical Department Urology   (Sweden)

^b PFIZER INC   (United States)

Author keywords

dry mouth; human; in vivo; incontinence; urinary bladder

Indexed keywords

11 [[4 [4 (DIETHYLAMINO)BUTYL] 1 PIPERIDYL]ACETYL] 5,11 DIHYDRO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPIN 6 ONE; 5 HYDROXYMETHYLTOLTERODINE; 6 CHLORO 5,10 DIHYDRO 5 [(1 METHYL 4 PIPERIDYL)ACETYL] 11H DIBENZO[B,E][1,4]DIAZEPIN 11 ONE; ATROPINE; DARIFENACIN; DRUG METABOLITE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PNU 200577; RECEPTOR SUBTYPE; TOLTERODINE; UNCLASSIFIED DRUG;

BLADDER FUNCTION; BLADDER INSTABILITY; CLINICAL TRIAL; CONFERENCE PAPER; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; HYPERREFLEXIA; INCONTINENCE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SALIVATION; TISSUE SPECIFICITY; URINE RETENTION; XEROSTOMIA;

ANIMALS; BENZHYDRYL COMPOUNDS; CRESOLS; HUMANS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; URINARY BLADDER;

EID: 0030903463     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00057-X     Document Type: Conference Paper

References (26)

1. A Report of the Royal College of Physicians: Incontinence. Causes, management and provision of services, London, UK (1995).
2. K.E. ANDERSSON, Pharmacol. Rev. 45 253-308 (1993).
3. P. WANG, G.R. LUTHIN and M.R. RUGGIERI, J.Pharmacol. Exp.Ther. 273 959-966 (1995).
4. Y.E. YARKER, K.L. GOA and A. FITTON, Drugs Aging 6 243-262 (1995).
5. L. NILVEBRANT, G. GLAS, Å. JÖNSSON and B. SPARF, Neurourol.Urodyn. 13 433-435 (1994)
6. L. NILVEBRANT, M. STAHL and K.E. ANDERSSON, Neurourol Urodyn 14 523-524 (1995)
7. L. NILVEBRANT, S. SUNDQUIST and P.G. GILLBERG, Neurourol.Urodyn 15 310-311 (1996)
8. P.G. GILLBERG, B. SPARF and L. NILVEBRANT, Neurourol. Urodyn. 15 308-309 (1996)
9. D.T. NEWGREEN, C.W.P. ANDERSON, A.J. CARTER and A.M. NAYLOR, Neurourol. Urodyn. 14 555-556 (1995).
10. F. DÖRJE, J. WESS, G. LAMBRECHT, R. TACKE, E. MUTSCHLER and M.R. BRANN, J. Pharmacol. Exp. Ther. 256 727-733 (1991).
11. J. WESS, G. LAMBRECHT, E. MUTSCHLER, M.R. BRANN and F. DÖRJE, Br. J. Pharmacol. 102 246-250 (1991).
12. H. NAERGER, C.H. FRY and L. NILVEBRANT, Neurourol.Urodyn. 14 524-526 (1995).
13. L. NILVEBRANT, Acta pharmacol et toxicol 59 (Suppl. I) 1-45 (1986).
14. F.J. EHLERT and E.A. THOMAS, Life Sci 56 965-971 (1995).
15. R.M. EGLEN, H. REDDY, N. WATSON and R.A.J. CHALLIS, TIPS 15 114-119 (1994).
16. R.M. EGLEN and N. WATSON, Pharmacology & Toxicology, 78 59-68 (1996)
17. P.G. GILLBERG, A.R. MODIRI and B. SPARF, Neurourol.Urodyn. 13 435-436 (1994).
18. G.T. SOMOGYI, M. TANOWITZ and W.C. DE GROAT, J. Physiol. 480 81-89 (1994).
19. N. BRYNNE, M. STAHL, B. HALLEN, P.O. EDLUND and L. PALMÉR, Thérapie Supplement. Abstracts of EACPT (1995) (Abstr. 353).
20. G. LARSSON, B. HALLÉN and L. NILVEBRANT, Proc. Int. Continence Society, 26th Ann. Meeting (1996) (Abstr. 237).
21. H. POSTLIND and S. ANDERSSON, Xth Int. Symp. on Microsomes and Drug Oxidation, UCLA, Los Angeles, July 21-24 (1996) (Abstr. 66).
22. M. STAHL, N. BRYNNE, B. EKSTRÖM, B. HALLÉN, A. MATTIASSON and K.E. ANDERSSON, Thérapie,Supplement. Abstracts of EACPT (1995) (Abstr. 355).
23. M.M.S. STAHL, B. EKSTRÖM, B. SPARF, A. MATTIASSON and K.-E. ANDERSSON, Neurourol. Urodyn. 14 647-656 (1995).
24. L. RENTZHOG, P. ABRAMS, L. CARDOZO, M. FALL, E. NELSON and S.L. STANTON, Proc. Int.Continence Society, 25th Ann. Meeting (1995) (Abstr. 114).
25. E.J. MESSELINK, J.M. SOLER, H. MADERSBACHER, J.W. THÜROFF, G. AMARENCO and Ph.E.V. VAN KERREBROECK, Proc. Int. Continence Society, 25th Ann. Meeting (1995) (Abstr. 142).
26. P. ABRAMS, S. JACKSON, A. MATTIASSON, K. KRISHNAN and L. HAENDLER, Proc. Int. Continence Society, 26th Ann. Meeting (1996) (Abstr. 259).